nbix reported 71.1M in ingrezza sales which beated consensus by $7.3M. script growth was a massive 12500 vs 9100 a qt earlier. Current TRx translates patient count to roughly 4000-4500. This trajectory is well above its curve to reach 30k patients by 2023/2024 or 2.25B in sales(30k*75k). Also management has initiated an early extension trial for TS(another 2.5B in sales), known as T-FORCE platinum. This early initiation further provides confidence in its belief in the TS program. Also a SNDA is expected in 1H of 2019. Management continues to fire on all cylinders and are moving at a very rapid pace. The current stock price seems to undermine elagolix, TS and CAH potential. if it was fully priced in, stock should be trading above a 200+ PPS. I am LONG NBIX $XBI $IBB $SPY $DIA $QQQ $TEVA